ArticleBMC gastroenterology2026
Development and validation of a risk model for non-fatty chronic liver disease in middle-aged and older adults with metabolic syndrome.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNon-fatty chronic liver disease (CLD) is a major global health burden. Individuals with metabolic syndrome (MetS) have a substantially increased risk of developing non-fatty CLD. This study aimed to develop and validate risk prediction models for non-fatty CLD among middle-aged and older adults with MetS.
methodsData were obtained from the China Health and Retirement Longitudinal Study (CHARLS). The dataset was randomly divided into a training set (70%) and a testing set (30%). Least absolute shrinkage and selection operator (LASSO) logistic regression with ten-fold cross-validation was applied for predictor selection. Two risk prediction models and nomograms were constructed to predict the 9-year risk of incident non-fatty CLD: a non-laboratory model and a laboratory-based model. Model performance was evaluated using receiver operating characteristic curves and the area under the curve (AUC), calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC).
resultsAmong 4,748 participants, 253 developed non-fatty CLD during the approximately 9-year follow-up period, yielding a cumulative incidence of 5.33%. LASSO regression identified six non-laboratory predictors (male sex, dyslipidemia, heart disease, kidney disease, digestive system disease, and lack of piped water) in non-laboratory model and two additional laboratory indicators (low platelet count and high triglyceride level) in laboratory model. The non-laboratory model achieved AUCs of 0.762 (95% CI: 0.720-0.803) and 0.744 (95% CI: 0.680-0.808) in the training and testing sets, respectively, while the laboratory model showed improved discrimination with AUCs of 0.792 (95% CI: 0.754-0.830) and 0.769 (95% CI: 0.712-0.825). Calibration curves demonstrated good agreement between predicted and observed risks. DCA and CIC indicated that both models provided meaningful clinical net benefit across a wide range of risk thresholds.
conclusionBoth the non-laboratory and laboratory-based risk prediction models for 9-year risk of non-fatty CLD in individuals with MetS demonstrated good predictive performance. However, given the reliance on self-reported outcome data without objective confirmation, these findings should be considered exploratory and hypothesis-generating. Pending external validation, these models may eventually serve as practical tools for early risk stratification in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.